文献速递消化道肿瘤与早癌消化内镜

液体活检无创识别T1结直肠癌淋巴结转移的检测方法

A Liquid Biopsy Assay for Noninvasive Identification of Lymph Node Metastases in T1 Colorectal Cancer.
PubMed 文献 · Gastroenterology · 2021-04-02

本研究将组织转录组生物标志物转化为血液液体活检,用于高危T1结直肠癌患者淋巴结转移的无创检测。研究分析了330例标本,包括训练队列46例和验证队列142例血清及匹配组织,建立4种miRNA和5种mRNA的转录组面板及风险分层模型。模型在验证队列中AUC为0.82,风险分层模型AUC达0.90,仅18%患者被过度治疗,优于现有病理特征(92%)。

要点

  • 液体活检面板由4种miRNA和5种mRNA组成,可无创识别T1结直肠癌淋巴结转移。
  • 风险分层模型结合临床风险因素,AUC达0.90,为淋巴结转移的独立预测因子。
  • 模型将潜在过度治疗限制在18%,显著优于现行病理特征(92%)。

核心结论

  • 新型风险分层模型可无创识别T1结直肠癌淋巴结转移,有望避免高危患者不必要的手术。

研究设计与样本

  • 分析330例高危T1结直肠癌标本,含训练队列46例和验证队列142例血清及142例匹配FFPE样本。
  • 采用定量逆转录PCR和逻辑回归分析开发转录组面板并建立风险分层模型。

主要发现

  • 训练队列中面板识别淋巴结转移的AUC为0.86(95%CI 0.72-0.94)。
  • 验证队列中面板AUC为0.82(95%CI 0.74-0.88)。
  • 风险分层模型AUC为0.90,单因素OR 37.17(95%CI 4.48-308.35,P<.001),多因素OR 17.28(95%CI 1.82-164.07,P=.013)。
  • 模型将潜在过度治疗限制在18%,现行病理特征为92%。

关键数值与推荐

  • 转录组面板包含4种miRNA(miR-181b、miR-193b、miR-195、miR-411)和5种mRNA(AMT、FOXA1、PIGR、MMP1、MMP9)。

临床怎么用

  • 对于常规风险分类为高危的T1结直肠癌患者,可考虑使用该液体活检模型无创评估淋巴结转移风险,辅助手术决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We recently reported use of tissue-based transcriptomic biomarkers (microRNA [miRNA] or messenger RNA [mRNA]) for identification of lymph node metastasis (LNM) in patients with invasive submucosal colorectal cancers (T1 CRC). In this study, we translated our tissue-based biomarkers into a blood-based liquid biopsy assay for noninvasive detection of LNM in patients with high-risk T1 CRC. METHODS: We analyzed 330 specimens from patients with high-risk T1 CRC, which included 188 serum samples from 2 clinical cohorts-a training cohort (N = 46) and a validation cohort (N = 142)-and matched formalin-fixed paraffin-embedded samples (N = 142). We performed quantitative reverse-transcription polymerase chain reaction, followed by logistic regression analysis, to develop an integrated transcriptomic panel and establish a risk-stratification model combined with clinical risk factors. RESULTS: We used comprehensive expression profiling of a training cohort of LNM-positive and LMN-negative serum specimens to identify an optimized transcriptomic panel of 4 miRNAs (miR-181b, miR-193b, miR-195, and miR-411) and 5 mRNAs (AMT, forkhead box A1 [FOXA1], polymeric immunoglobulin receptor [PIGR], matrix metalloproteinase 1 [MMP1], and matrix metalloproteinase 9 [MMP9]), which robustly identified patients with LNM (area under the curve [AUC], 0.86; 95% confidence interval [CI], 0.72-0.94). We validated panel performance in an independent validation cohort (AUC, 0.82; 95% CI, 0.74-0.88). Our risk-stratification model was more accurate than the panel and an independent predictor for identification of LNM (AUC, 0.90; univariate: odds ratio [OR], 37.17; 95% CI, 4.48-308.35; P < .001; multivariate: OR, 17.28; 95% CI, 1.82-164.07; P = .013). The model limited potential overtreatment to only 18% of all patients, which is dramatically superior to pathologic features that are currently used (92%). CONCLUSIONS: A novel risk-stratification model for noninvasive identification of T1 CRC has the potential to avoid unnecessary operations for patients classified as high-risk by conventional risk-classification criteria.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Wada Y, Shimada M, Murano T, et al. A Liquid Biopsy Assay for Noninvasive Identification of Lymph Node Metastases in T1 Colorectal Cancer. Gastroenterology. 2021. PMID: 33819484. doi:10.1053/j.gastro.2021.03.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。